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Abstract 
Bisphosphonates inhibit bone resorption and are used to treat a range of pathologies, including Paget disease, os-
teoporosis, multiple myeloma and metastases associated with breast or prostate cancer. At present, there is no ef-
fective treatment for bisphosphonate induced osteonecrosis, so prevention is extremely important. Since quality of 
life deteriorates for those suffering osteonecrosis, maximum precautions should be taken with patients at risk, and 
especially whenever oral surgery, including dental implant placement, is contemplated. Dentists and oral or maxil-
lofacial surgeons must keep up to date with the latest approaches to prevention, particularly when treating patients 
who are presently taking, or who will be taking bisphosphonates and are also candidates for dental implants.
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Introduction
Bisphosphonates are a group of drugs that inhibit bone 
resorption. They act on osteoclasts, inhibiting chemot-
axis, cutting osteoclast lifespan, slowing their activity 
and inducing apoptosis. There are important differenc-
es between bisphosphonates administered intravenous-
ly and those taken orally. Intravenous bisphosphonates 
are used to reduce bone pain, malignant hypercalcemia, 
skeletal complications suffered by patients with Paget’s 
disease or myeloma and for the treatment of bone me-
tastasis derived from various cancers (1). Oral bispho-
sphonates are used for the treatment of osteoporosis, 
Paget’s disease and imperfect osteogenesis (Table 1).
The nuclear structure of bisphosphonates consists of 
two phosphate groups joined by a single carbon atom 
(2). Bisphosphonates that include a nitrogen molecule 
in their bioactive structure are more powerful. They 
accumulate in maximum concentration in the osseous 
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Active ingredient Trade name Administered
Alendronate Fosamax®,Fosavance® Orally
Etidronate Osteum®, Difosfen® Orally
Risedronate Actonel®, Acrel® Orally
Tiludronate Skelid® Orally
Zoledronate Zometa®, Aclasta® Intravenously
Pamidronate Aredia
®, Linoten®, 
Pamifos®, Xinsidona® Intravenously
Ibandronate Bondronat® Orally, Intravenously
Clodronate Bonefos® Orally, Intravenously
Table 1. Different types of bisphosphonate in current usage.
Table 2. Articles on implant placement in patients treated with bisphosphonates.
AUTHORS YEAR PUBLICATION SAMPLE Nº OF IM-PLANTS
 BISPHOS-
PHONA-
TES
TAKEN 
ORALLY 
IMPLANTS 
LOST
CASES OF 
OSTEO-
NECROSIS
Marx et al.
(1) 2005
J. Oral. Maxillo-
fac. Surg.
119 cases of 
osteonecrosis 
in patients 
treated with 
oral bisphos-
phonates
Not stated 3 Not stated 4 deriving from implant placement
Jeffcoat
(13) 2006
Int. J. Oral 
Maxillofac. Im-
plants
25 102
25 (for 3±0.1 
years on 
average)
None None
Wang et al.
(14) 2007 J. Periodontal 1 5
1 (for more 
than 10 
years)
None 1
Marx et al.
(15) 2007
J. Oral Maxillo-
fac. Surg.
30 cases of 
osteonecrosis 
in patients 
treated with 
oral bisphos-
phonates
Not stated 30 Not stated 2 deriving from implant placement
Fugazzotto 
et al.
(12)
2007 J. Periodontal 61 169 61 (3,3 years on average) None
Torus exposure 
around one post-
extraction implant 
which closed 
spontaneously 
after four weeks 
Grant et al.
(10) 2008
J. Oral Maxillo-
fac. Surg. 115 468
89
(33 for more 
than
 3 years) 
2 None
Bell et al.
(11) 2008
J. Oral Maxillo-
fac. Surg. 42 101 Not stated 5 None
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matrix and in osteoclasts, mainly during the first 24-48 
hours of medication. Concentration remains high over 
long periods.
In 2007, the American Association of Oral and Maxil-
lofacial Surgeons defined osteonecrosis induced by bis-
phosphonates as the presence of unhealed exposed bone 
in the maxilla or mandible, persisting for more than eight 
weeks in patients who have taken systemic bisphospho-
nates but who have not received localized radiotherapy.
In recent years maxillary cases of osteonecrosis fol-
lowing oral surgery, particularly exodontias, have been 
related to treatment with intravenous or oral bisphos-
phonates. The main intravenous bisphosphonates im-
plicated are Pamidronate (Aredia®) and Zoledronate 
(Zometa®). Cases of osteonecrosis induced by oral 
bisphosphonates have also been recorded, although less 
frequently, particularly Alendronate (Fosamax®) and 
Risedronate (Actonel® or Acrel®).
Marx et al. (1) claim that for patients taking bisphos-
phonates, osteonecrosis seems to be related to a lack 
of vascular supply in combination with a lack of bone 
remodeling and regeneration. Other factors which seem 
to influence the occurrence of osteonecrosis in maxil-
lary structures (but not in other osseous structures) are 
that the maxilla receives an increased blood supply and 
shows faster osseous remodeling due to the everyday 
masticatory action of the teeth. Two other relevant fac-
tors may be that mandibular arteries are terminal ar-
teries and that there are a large number of pathologies 
of dental origin that require dental treatments that then 
have repercussions for maxillary and mandibular bone. 
Materials and Methods
A bibliographic search was carried out using Pub-Med 
ending in October, 2008. The search terms used were: 
oral bisphosphonates, dental implants, osteonecrosis, 
maxillary/maxilla.
The objective of this article was to produce an updated 
bibliographic review of dental implants in patients un-
dergoing treatment with oral bisphosphonates. 
Results
Since 2003, when Marx (4) published a series of thirty-
six cases of osteonecrosis associated with bisphospho-
nates, numerous studies have been carried out which 
relate the occurrence of osteonecrosis in maxillary 
structures, mainly the mandible, associated with intra-
venous bisphosphonates following oral surgery, mainly 
exodontias (1, 4-9).
However, the topic of the present review is the incidence 
of osteonecrosis related to dental implant placement in 
patients undergoing treatment with oral bisphospho-
nates; our findings are shown in table 2. 
Discussion
Administering bisphosphonates orally to post-meno-
pausal women for the treatment of osteoporosis is fairly 
frequent nowadays. Nevertheless, the literature includes 
only a small number of cases of maxillary osteonecrosis 
following surgery in the buccal cavity of patients taking 
oral bisphosphonates (1,7). The length of treatment with 
these drugs would appear to be a relevant factor, as the 
cases of osteonecrosis described occur in patients tak-
ing the drug for more than three years. Grant et al. (10) 
have described a series of 115 cases, of which eighty-
nine took bisphosphonates orally prior to implant sur-
gery and thirty-three of them for more than three years. 
No cases of osteonecrosis appeared and there were only 
two implants that failed to osseointegrate; of these, one 
patient had taken oral bisphosphonates for four years 
preceding surgery. Of the 115 patients, thirty-two of 
them were given sinus lifts, and six of these patients 
were on bisphosphonates for more than three years prior 
to surgery. Bell et al. obtained similar results published 
in an article that describes a series of 101 implants in 
forty-two patients; not a single case of osteonecrosis oc-
curred but five implants failed in five different patients. 
Three of these five patients had taken bisphosphonates 
for more than three years. Nevertheless, four of these 
patients had received other implants at the same time 
which osseointegrated successfully. Of sixty-eight bone 
grafts carried out, there was only one failure.
Of the sixty-one patients treated with 169 implants by 
Fugazzotto et al. (12) with an average bisphosphonate 
medication period of 3.3 years, there was one case of 
bone exposure of the torus around a post-extraction 
implant, which closed spontaneously after four weeks. 
Jeffcoat (13) found that, of 102 implants in patients tak-
ing bisphosphonates over periods ranging between one 
and four years (average 3±0.1 years) before surgery, not 
a single implant was lost. There was no occurrence of 
osteonecrosis and no significant differences were found 
when results were compared with a control group who 
did not take the drug. Nevertheless, Wang et al. (14) 
published a case of five mandibular implants in a patient 
who had been taking alendronate orally for over ten 
years, producing an osseous defect with necrosis around 
one of the implants six weeks after surgery; Marx et 
al. (15) also found two cases of osteonecrosis resulting 
from implant surgery in patients who had taken bispho-
sphonates orally over periods of more than three years. 
Recommendations published by the American Dental 
Association (16) warn that the placement of dental im-
plants or guided bone regeneration involves an increased 
risk of osteonecrosis in patients undergoing treatment 
with oral bisphosphonates. Gomez et al. (17) state that 
generally, given the lack of research and the controversy 
surrounding dental implants for these patients, it is bet-
ter to avoid them altogether along with all other types of 
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oral surgery; Minguez-Serra et al. also propose avoid-
ing surgery except in cases of absolute necessity. Bagán 
et al. (18) have published a series of recommendations 
for the prevention of osteonecrosis for patients with can-
cer who take bisphosphonates intravenously. The Span-
ish Society of Oral and Maxillofacial Surgeons elected 
a committee of scientists to produce a consensus docu-
ment (19) on diagnosis, prevention and treatment of 
maxillary osteonecrosis induced by bisphosphonates. 
The American Association of Oral and Maxillofacial 
Surgeons do not contraindicate dental implant place-
ment in patients who have been taking bisphosphonates 
orally for under three years prior to surgery providing 
they do not present other risk factors such as medica-
tion with corticosteroids or advanced age (over seventy 
years). After three years treatment with the drug it would 
appear advisable to cease medication for a minimum of 
three months before carrying out any kind of surgical 
intervention in the oral cavity after which the drug can 
be administered again once the surgery has completely 
healed. In the case of dental implants, a minimum of 
three months after surgery is recommended before the 
medication can be administered again. However, in the 
literature reviewed, most texts described implant place-
ment in patients who had taken bisphosphonates orally 
for more than three years without any cases of osteone-
crosis occurring, with the exception of a single case in 
which necrosis around two implants was observed ra-
diologically and the two cases described by Marx et al. 
(15). In these retrospective studies, the patients who had 
been receiving the medication for over three years did 
not stop taking it, probably because they were treated 
before the findings of these panels of experts were pu-
blished.
Marx et al. (15) recommend a blood test, the serum C-
terminal telopeptide test (CTX) on an empty stomach, 
in order to evaluate the risk of osteonecrosis in patients 
who have been administered bisphosphonates for lon-
ger than three years. Values obtained that are greater 
than 150 pg/mL permit any kind of surgery to be per-
formed with minimum risk and without needing to sus-
pend medication. When values lower than 150 pg/mL 
are obtained, then medication should cease for a period 
of between four and six months or an alternative treat-
ment option involving other types of prosthesis should 
be sought. Nevertheless, Bágan et al. (20) did not find 
a significant relation between this test and the number 
of exposed osseous areas or the size of necrotic areas 
in cancer patients treated intravenously with bisphos-
phonates.
Conclusions
It is necessary to carry out a greater number of longi-
tudinal studies of implant placement in patients taking 
bisphosphonates orally in order to determine the safety 
of this procedure for this group of patients. More scien-
tific evidence is also required in order to validate CTX 
testing as a technique for the prevention of osteonecrosis 
for these patients and therefore the introduction or non-
introduction of this test into pre-surgical protocols.  
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